Dyadic Issued New U.S. Patent
News Nov 11, 2013
The invention relates to methods of developing and producing novel enzymes, more specifically for the development of a variety of fungal enzymes. Also described in the patent is the encoding of nucleic acid molecules for such enzymes, compositions, recombinant, and genetically modified host cells, and methods of use.
In addition, the patent also addresses methods to convert lignocellulosic biomass into fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. Large amounts of carbohydrates in plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce biofuels such as Cellulosic Ethanol and a variety of bio-based chemicals. Additionally, the patent addresses methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, biorefining, deinking and biobleaching of paper and pulp, and treatment of waste streams.
Dyadic's President and CEO, Mark Emalfarb, stated, "This latest patent builds upon our family of patents that address the conversion of lignocellulosic biomass into fermentable sugars for the production of renewable biofuels and bio-based chemicals using our proprietary C1 technology. This latest patent adds to our comprehensive IP portfolio further protecting our C1 protein expression system and the products derived therefrom, which continues to attract blue chip customers, partners, and collaborators."
This patent is the thirteenth U.S. patent issued to Dyadic adding to its portfolio of 41 international patents, 23 pending international and 11 pending U.S. patent applications which cover various features of Dyadic's proprietary technologies.
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Sequencing Shows How Evolution Can Undermine Bioprocess CommercializationNews
Rapid evolution can suppress the effect of pro-production genes in biochemical processes.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018